Azedra: Phase II resumed

Progenics restarted dosing patients in an open-label, pivotal U.S. Phase II trial evaluating 2 doses of 500 mCi or 8 mCi/kg Azedra given about 3 months apart in about 75 patients ages >=12. In late 20...